PITRM1: A Potential Drug Target and Biomarker for Mitochondrial Enzyme-Driven diseases

Target Name: PITRM1

NCBI ID: G10531

PITRM1

PITRM1: A Potential Drug Target and Biomarker for Mitochondrial Enzyme-Driven diseases

Introduction

Predictive and therapeutic approaches for diseases caused by dysfunctional mitochondria have gained significant attention in recent years. Mitochondria are essential organelles that play crucial roles in energy metabolism and have been implicated in various neurological and cardiovascular diseases. PITRM1, a protein encoded by the mitochondrial gene, is a pro-inflammatory protein that has been associated with various cellular and physiological processes. In this article, we will explore the potential implications of PITRM1 as a drug target and biomarker for mitochondrial diseases.

PITRM1: Structure, Function, and Interaction with Mitochondria

PITRM1 is a 21-kDa protein that is predominantly localized to the mitochondria. It belongs to the peroxisome family 1 (P1) and is part of the mitochondrial inner membrane (M1) protein 2 (PMM2) subfamily. PITRM1 is composed of a N- terminal transmembrane domain, a coiled-coil region, and a C-terminal protein domain that contains a putative catalytic site and several potential interacting partners (Figure 1).

PITRM1 is involved in various cellular processes, including inflammation, stress response, and metabolism. It has been shown to regulate the expression of several genes involved in cell signaling pathways, such as NF-kappa, NF-kappa-B, and AP-1. PITRM1 has also been shown to play a role in the regulation of mitochondrial dynamics and function, including the dynamics of mitochondrial fission and fusion.

In addition to its role in cellular signaling pathways, PITRM1 has also been implicated in the development and progression of various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that PITRM1 is overexpressed or hyperactive in the brains of individuals with these disorders, and that these changes in PITRM1 expression may contribute to the pathogenesis of these diseases.

PITRM1 as a Drug Target

The therapeutic potential applications of PITRM1 are vast, and the scientific literature has generated significant interest in its potential as a drug target. One of the main targets of PITRM1 is the regulation of mitochondrial dynamics and function. Activating PITRM1 has been shown to increase mitochondrial fission and fusion, leading to an increase in mitochondrial dysfunction and the formation of mitochondrial vacuoles, which are hallmark pathological features of neurodegenerative diseases.

PITRM1 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in neurodegenerative diseases, such as the regulation of autophagy and apoptosis. Overexpression of PITRM1 has been shown to increase the levels of autophagy-associated protein (AP- 1), a protein that is involved in the regulation of autophagy, and to decrease the levels of brain-derived neurotrophic factor (BDNF), a protein that is involved in the regulation of apoptosis.

In addition to its role in neurodegenerative diseases, PITRM1 has also been shown to be involved in other cellular processes that are important for human health, such as cancer cell signaling pathways and the regulation of inflammation.

PITRM1 as a Biomarker

PITRM1 has also been shown to be a potential biomarker for various diseases, including neurodegenerative diseases. The levels of PITRM1 have been shown to be altered in individuals with neurodegenerative diseases, and these changes in PITRM1 expression may contribute to the path

Protein Name: Pitrilysin Metallopeptidase 1

Functions: Metalloendopeptidase of the mitochondrial matrix that functions in peptide cleavage and degradation rather than in protein processing (PubMed:10360838, PubMed:16849325, PubMed:19196155, PubMed:24931469). Has an ATP-independent activity (PubMed:16849325). Specifically cleaves peptides in the range of 5 to 65 residues (PubMed:19196155). Shows a preference for cleavage after small polar residues and before basic residues, but without any positional preference (PubMed:10360838, PubMed:19196155, PubMed:24931469). Degrades the transit peptides of mitochondrial proteins after their cleavage (PubMed:19196155). Also degrades other unstructured peptides (PubMed:19196155). It is also able to degrade amyloid-beta protein 40, one of the peptides produced by APP processing, when it accumulates in mitochondrion (PubMed:16849325, PubMed:24931469, PubMed:26697887). It is a highly efficient protease, at least toward amyloid-beta protein 40 (PubMed:24931469, PubMed:29764912, PubMed:29383861). Cleaves that peptide at a specific position and is probably not processive, releasing digested peptides intermediates that can be further cleaved subsequently (PubMed:24931469). It is also able to degrade amyloid-beta protein 42 (PubMed:29764912)

The "PITRM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PITRM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets